The present invention refers to a fusion protein or a protein complex comprising a DNA binding protein (DnaBP), a nucleobase modifying protein (NMP), and a Base Excision Repair associated protein (BERAP. Also, described herein are a method of replacing a cytosine with a guanine on a DNA strand in a cell and a method of treating a subject having or suspected of having a disease or disorder.

The present invention refers to a fusion protein or a protein complex comprising a DNA binding protein (DnaBP), a nucleobase modifying protein (NMP), and a Base Excision Repair associated protein (BERAP. Also, described herein are a method of replacing a cytosine with a guanine on a DNA strand in a cell and a method of treating a subject having or suspected of having a disease or disorder.

The present disclosure belongs to the field of biomedicine. Specifically, the present disclosure relates to a circular RNA molecule, a cyclization precursor RNA molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a composition and use thereof in targeted degradation of a protein of interest, as well as a method for preventing or treating a disease. The circular RNA molecule has good membrane permeability, is easily delivered into cells, and has high-efficiency in vivo protein targeted degradation activity. The circular RNA molecule of the present disclosure successfully achieves inhibition of tumor growth, which proves the in vivo protein degradation activity of bio-PROTACs for the first time, and provides a positive and effective treatment solution for the treatment of diseases such as tumor.

The present disclosure belongs to the field of biomedicine. Specifically, the present disclosure relates to a circular RNA molecule, a cyclization precursor RNA molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a composition and use thereof in targeted degradation of a protein of interest, as well as a method for preventing or treating a disease. The circular RNA molecule has good membrane permeability, is easily delivered into cells, and has high-efficiency in vivo protein targeted degradation activity. The circular RNA molecule of the present disclosure successfully achieves inhibition of tumor growth, which proves the in vivo protein degradation activity of bio-PROTACs for the first time, and provides a positive and effective treatment solution for the treatment of diseases such as tumor.

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

The present invention relates to uses of threonyl-tRNA synthetase (TARS) derived from Akkermansia muciniphila or a fragment thereof as an active ingredient for prevention, alleviation, and treatment of an inflammatory disease. The Akkermansia muciniphila TARS or a fragment thereof according to the present invention promotes the differentiation of M2 macrophages, which are anti-inflammatory macrophages, to multiply macrophages, thereby increasing the secretion of IL-10 as an anti-inflammatory cytokine, leading to the proliferation of B cells to result in an anti-inflammatory effect, and thus was verified to show alleviation effects of not only inflammatory diseases but also immune diseases, infectious diseases, and metabolic diseases accompanied by inflammation, and to have excellent effects in the prevention or treatment of an inflammatory bowel disease (IBD).

The present invention relates to uses of threonyl-tRNA synthetase (TARS) derived from Akkermansia muciniphila or a fragment thereof as an active ingredient for prevention, alleviation, and treatment of an inflammatory disease. The Akkermansia muciniphila TARS or a fragment thereof according to the present invention promotes the differentiation of M2 macrophages, which are anti-inflammatory macrophages, to multiply macrophages, thereby increasing the secretion of IL-10 as an anti-inflammatory cytokine, leading to the proliferation of B cells to result in an anti-inflammatory effect, and thus was verified to show alleviation effects of not only inflammatory diseases but also immune diseases, infectious diseases, and metabolic diseases accompanied by inflammation, and to have excellent effects in the prevention or treatment of an inflammatory bowel disease (IBD).

The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods, and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.

The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods, and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.